Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Berruti
Alfredo
A
Buttigliero
Consuelo
C
Dogliotti
Luigi
L
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D009570:Nitriles / Q000627:therapeutic use; D017697:Premenopause; D014230:Triazoles / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use*; D014815:Vitamins / Q000627:therapeutic use; D000077211:Zoledronic Acid
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D009570:Nitriles; D014230:Triazoles; D014815:Vitamins; D014807:Vitamin D; D000077384:Anastrozole; D000077211:Zoledronic Acid